Asit Kumar Chakraborty*
Associate Professor of Biochemistry, OIST, Department of Biotechnology, Vidyasagar University, Midnapore, West Bengal, India
*Corresponding Author: Asit Kumar Chakraborty, Associate Professor of Biochemistry, OIST, Department of Biotechnology, Vidyasagar University, Midnapore, West Bengal, India.
Received: November 25, 2020; Published: November 30, 2020
Invisible SARS-CoV-2 27kb single (+)-stranded RNA virus (120nm) has crossed limit by killing 3 millions and affecting 600 millions . Severe COVID-19 is more common in adults aged ~70 years and older and in individuals with comorbidities such as hypertension, diabetes, cardiovascular disease, and chronic respiratory disease . Indian Government as well as other G-20 nations declared war against Corona virus. Coronavirus has structural proteins (S, M, N, E) and two large polyproteins which degraded into sixteen non-structural proteins (nsp1-16) . No new targeted drug was discovered and vaccine is only new hope. Presently, at least ten vaccine candidates are in stage-III clinical trials on 20 - 40 thousand human worldwide [4-8]. It is expected that India should be starting vaccination in the middle of 2021 with a cost of few hundred to few thousand per dose. Vaccine usually is a protein or synthetic peptides from Corona virus that can elicits humoral antibody (IgG) as well as T-cell mediated ability to destroy virus.
Citation: Asit Kumar Chakraborty. “Molecular Targets and Biotechnological Exploration on Corona-Virus and Multi-Drug Resistant Bacteria". Acta Scientific Biotechnology 1.12 (2020): 25-26.
Copyright: © 2020 Asit Kumar Chakraborty. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.